Skip to main content
Guest homeNews home
Story
21 of 50

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial  Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound  CNBC Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug  The New York Times Lilly seeks FDA approval of oral GLP-1 after success in obesity switching study  FirstWord Pharma Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial  BioPharma Dive

Latest News